<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822066</url>
  </required_header>
  <id_info>
    <org_study_id>LA-003</org_study_id>
    <nct_id>NCT02822066</nct_id>
  </id_info>
  <brief_title>Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <brief_summary>
    <textblock>
      The pupose of this study is to evaluate the safety and efficacy of irreversible
      electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used
      preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests
      including the tumor markers to evaluate the general condition of patients. Intraoperative
      US/CEUS/CT would be applied to monitor ablation lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>60 patients of refractory neoplasms in liver and pancreas with irreversible electroporation-related effectivity as assessed by MRI</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Refractory Neoplasms</condition>
  <arm_group>
    <arm_group_label>IRE for refractory neoplasms in liver and pancreas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the safety and efficacy of irreversible electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients. Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electroporation</intervention_name>
    <description>Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas</description>
    <arm_group_label>IRE for refractory neoplasms in liver and pancreas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with hepatic portal focal lesion adjacent to important structures like bile
             duct and portal blood vessels, or intolerant surgery.

          2. Patients with pancreatic cancer adjacent to blood vessels, or intolerant surgery.

        Exclusion Criteria:

        Patients with:

          1. Metal in the body

          2. ChildPugh ≥ 3

          3. Long-term use of anticoagulant drugs including warfarin, clopidogrel bisulfate

          4. Poor cardiac or renal function with intolerant surgery or anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tian'an Jiang, Phd</last_name>
    <phone>+86 18857127666</phone>
    <email>tiananjiang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guo Tian, Master</last_name>
    <phone>+86 13600529967</phone>
    <email>871035504@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tian'an Jiang, Phd</last_name>
      <phone>+86 18857127666</phone>
      <email>tiananjiang@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Guo Tian, Master</last_name>
      <phone>+86 13600529967</phone>
      <email>871035504@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Dollinger M, Zeman F, Niessen C, Lang SA, Beyer LP, Müller M, Stroszczynski C, Wiggermann P. Bile Duct Injury after Irreversible Electroporation of Hepatic Malignancies: Evaluation of MR Imaging Findings and Laboratory Values. J Vasc Interv Radiol. 2016 Jan;27(1):96-103.</citation>
    <PMID>26777402</PMID>
  </results_reference>
  <results_reference>
    <citation>Froud T, Venkat SR, Barbery KJ, Gunjan A, Narayanan G. Liver Function Tests Following Irreversible Electroporation of Liver Tumors: Experience in 174 Procedures. Tech Vasc Interv Radiol. 2015 Sep;18(3):140-6. doi: 10.1053/j.tvir.2015.06.004. Epub 2015 Jun 18.</citation>
    <PMID>26365543</PMID>
  </results_reference>
  <results_reference>
    <citation>Hosein PJ, Echenique A, Loaiza-Bonilla A, Froud T, Barbery K, Rocha Lima CM, Yrizarry JM, Narayanan G. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. J Vasc Interv Radiol. 2014 Aug;25(8):1233-1239.e2. doi: 10.1016/j.jvir.2014.04.007. Epub 2014 May 24.</citation>
    <PMID>24861662</PMID>
  </results_reference>
  <results_reference>
    <citation>Belfiore MP, Ronza FM, Romano F, Ianniello GP, De Lucia G, Gallo C, Marsicano C, Di Gennaro TL, Belfiore G. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience. Int J Surg. 2015 Sep;21 Suppl 1:S34-9. doi: 10.1016/j.ijsu.2015.06.049. Epub 2015 Jun 25.</citation>
    <PMID>26118600</PMID>
  </results_reference>
  <results_reference>
    <citation>Lambert L, Horejs J, Krska Z, Hoskovec D, Petruzelka L, Krechler T, Kriz P, Briza J. Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience. Neoplasma. 2016;63(2):269-73. doi: 10.4149/213_150611N326.</citation>
    <PMID>26774149</PMID>
  </results_reference>
  <results_reference>
    <citation>Paiella S, Butturini G, Frigerio I, Salvia R, Armatura G, Bacchion M, Fontana M, D'Onofrio M, Martone E, Bassi C. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Dig Surg. 2015;32(2):90-7. doi: 10.1159/000375323. Epub 2015 Feb 28.</citation>
    <PMID>25765775</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effectivity</keyword>
  <keyword>safety</keyword>
  <keyword>irreversible electroporation</keyword>
  <keyword>liver</keyword>
  <keyword>pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

